Navigation Links
Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
Date:8/4/2009

atment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to future clinical development plans for our product candidates. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of our product candidates, and the indications for which our product candidates might be developed. There can be no guarantee that the results of preclinical studies or clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contain
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
2. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
3. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
4. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
5. Oncothyreon announces closing of $11.1 million registered direct financing
6. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
7. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
8. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
9. Oncothyreon reports first quarter 2009 financial results
10. Oncothyreon regains compliance with NASDAQ listing requirements
11. Oncothyreon to present at Invest Northwest 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
(Date:9/29/2014)... at the forefront of diagnostics today, with imaging ... tomography), scanning, and NMR (nuclear magnetic resonance) increasing ... problems of image resolution and quality still limit ... tissue. A solution is hyperpolarization, which involves injecting ... quality by following the distribution and fate of ...
(Date:9/29/2014)... conflicts in Iraq and Afghanistan, more than 300,000 soldiers ... injury caused by exposure to bomb blasts and ... Symptoms of traumatic brain injury can range from the ... severe impairments in memory and cognition. , Since ... critical importance and complexity of this problem, and has ...
(Date:9/29/2014)... Va. , Sept. 29, 2014  Ten ... the fields of cartilage repair, regeneration, allograft reconstruction ... from around the world gathered to discuss the ... Health Institute of Regenerative Medicine symposium, Cartilage ... . Topics included Orthopedic Biosurgery, Minced Juvenile Allograft, ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... Dendreon Corporation,(Nasdaq: DNDN ) today announced ... NEUVENGE, an investigational active cellular immunotherapy, in the,August ... The article highlights,the safety profile, immune response and ... cancer who have failed standard,therapy. "In addition ...
... Inc., a biotechnology company developing pharmaceutical products for ... dollar financing deal. The majority of the funding, ... the remainder was borrowed from the Madison Development ... Funds, a private investment firm. The funds raised ...
... more than a marketing campaign and the involvement of ... managers, senior executives and middle managers responsible for creating ... play a vital role in marketing the brand. Employees ... work. , ,Be Your Message. Employer brand building ...
Cached Biology Technology:Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4Quintessence Secures Financing 2Quintessence Secures Financing 3Employer Brands Require More Than Slick Marketing 2
(Date:9/29/2014)... A University of Texas at Arlington research team says ... built in their lab could open doors for homeland ... be published in the Oct. 1 issue of ... and his co-authors describe a new method to fabricate ... and oxygen until a transparent ceramic is formed. ...
(Date:9/29/2014)... has received a five-year, $6 million grant for ... evaluation and development of safe and effective treatments ... from the National Institutes of Health, National Institute ... for Medication Development for Cocaine Use Disorder to ... guide decisions on moving forward with more expensive ...
(Date:9/29/2014)... For decades, planetary geologists have speculated that glaciers ... 2000-mile-long chasm that constitutes the Grand Canyon of ... that might have been carved by past glaciers ... observations have remained highly controversial and contested. ... College and the Freie Universitaet Berlin has identified ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3New VCU center to target cocaine addiction 2Glaciers in the Grand Canyon of Mars? 2Glaciers in the Grand Canyon of Mars? 3Glaciers in the Grand Canyon of Mars? 4Glaciers in the Grand Canyon of Mars? 5Glaciers in the Grand Canyon of Mars? 6Glaciers in the Grand Canyon of Mars? 7Glaciers in the Grand Canyon of Mars? 8Glaciers in the Grand Canyon of Mars? 9
... (Santa Barbara, Calif.) An international team of researchers ... that happens in virtually every cell of our bodies. ... folded chains of amino acids assume their specific shapes, ... widely: In the human body, proteins fold to become ...
... family history of liver cancer is reported to increase risk ... findings published in the May issue of Hepatology , ... Liver Diseases. The study also shows 70-fold elevated risk of ... markers for hepatitis B (HBV) or hepatitis C (HCV). ...
... Princeton University researchers have observed a self-degradation response to ... provide new answers to lingering questions among scientists about ... that depression is not solely linked to the neurotransmitter ... PLoS ONE , researchers based in the lab of ...
Cached Biology News:In protein folding, internal friction may play a more significant role than previously thought 2Family history of liver cancer increases risk of developing the disease 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 3Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 4
... xi 2-D system runs both gel dimensions in the ... can be separated in a single run using the ... in much the same manner as the slab gel ... slab gels may be cast in the casting stand. ...
... Application Series are a line of ... provide fast and reliable automated solutions ... robust "automation-friendly" building blocks, Caliper has ... less than conventional approaches, take up ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White solid. ... A brain-permeable and water soluble pyrimidinone compound ... + -competitive inhibitor of PARP (IC 50 ... for rhPARP1 and rmPARP2, respectively) with little ...
...
Biology Products: